
FDA Approves First-in-Class Microbiota-Based Live Biotherapeutic for C. Difficile Infection
Live-jslm (Rebyota; Ferring Pharmaceuticals) is indicated for the prevention of recurring Clostridioides difficile infection among patients 18 years of age and older after an antibiotic treatment.





























